Gold prices edge higher on raised Fed rate cut hopes
On Tuesday, Raymond (NSE:RYMD) James upheld its Outperform rating and $57.00 price target for BridgeBio Pharma (NASDAQ:BBIO) shares, representing a significant upside from the current trading price of $34.57. According to InvestingPro data, analyst targets for the $6.57 billion market cap company range from $36 to $95, with a strong consensus recommendation of 1.63 (where 1 is Strong Buy). Following the American College of Cardiology annual meeting ( ACC (NSE:ACC) 2025) held on the weekend, the firm’s analyst, Danielle Brill (AS:BRIL), provided insights into BridgeBio’s recent data presentations. The company presented additional analyses from its Phase 3 study, ATTRibute-CM, of acoramidis (Attruby) for the treatment of ATTR cardiomyopathy (ATTR-CM).
The new analyses highlighted acoramidis’s impact on several metrics, including TTR stabilization, efficacy within the ATTRv population, and improvements or stabilization in the NYHA class, which is a classification of the extent of heart failure. These findings are considered to further support the drug’s competitive profile against existing treatments for ATTR-CM. InvestingPro analysis shows BridgeBio maintains a strong financial position with a current ratio of 4.67, indicating robust liquidity to support its drug development programs. The company’s overall Financial Health Score is rated as GOOD, with particularly strong momentum metrics.
BridgeBio’s Attruby was compared to Alnylam’s recently approved drug vutrisiran, which also had data presented at the ACC 2025 from its HELIOS-B study. While acknowledging the competitor’s data, Raymond James views the evidence for acoramidis as favorable, particularly considering both the primary results and post hoc analyses. This is seen as a positive indicator for the continued strong market introduction of Attruby.
The maintained price target reflects Raymond James’ confidence in the potential market performance of BridgeBio’s lead product. The firm’s stance is based on the detailed data presented at the ACC 2025, which reinforces the drug’s competitive stance in the ATTR-CM treatment landscape.
BridgeBio Pharma’s focus on genetic diseases and targeted therapies, such as acoramidis for ATTR-CM, is part of its broader strategy to address conditions with significant unmet medical needs. The company’s commitment to advancing its pipeline is reflected in the ongoing research and development efforts. This strategy has contributed to impressive market performance, with the stock showing a 39.4% return over the past six months. InvestingPro subscribers have access to additional insights, including 6 more ProTips and a comprehensive Pro Research Report, which is available for over 1,400 US stocks.
In other recent news, BridgeBio Pharma has announced significant clinical advancements for its drug acoramidis, following a Phase 3 trial. The drug demonstrated a statistically significant benefit in reducing all-cause mortality and first cardiovascular-related hospitalizations among patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Meanwhile, the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, marketed as Beyonttra, for treating ATTR-CM, following promising results from both a Japanese and a global Phase 3 trial. The approval will lead to a $30 million milestone payment from Alexion (NASDAQ:ALXN), AstraZeneca (NASDAQ:AZN) Rare Disease, and future royalties on sales in Japan.
On the financial front, Redburn-Atlantic initiated coverage on BridgeBio Pharma with a Buy rating and a $50 price target, citing the rapid progress of the Attruby rollout. Cantor Fitzgerald maintained its Overweight rating and a $95 price target, noting the complexities of Medicare drug coverage and its potential impact on BridgeBio Pharma’s financial prospects. The firm also highlighted that BridgeBio does not qualify for a small biotech exemption under the Inflation Reduction Act, which could affect its competitive position. These developments underscore the company’s ongoing efforts to expand its market presence and address unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.